The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.
The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.
At all time points, consistently high levels of patient satisfaction were observed (>84% reporting much or very much improved).
The health system defended itself by claiming it had done nothing wrong, and that Dr T had a clear duty to inform it of the ...
(HealthDay News) — Increased consumption of dark chocolate, but not milk chocolate, is associated with a reduced risk for type 2 diabetes (T2D), according to a study published online Dec. 4 in The BMJ ...
Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens.
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with lupus nephritis may reduce the risk of progression to end-stage kidney disease (ESKD), according to a poster presentation ...
(HealthDay News) — During August 2021 to August 2023, the overall prevalence of anemia was 9.3% among people aged 2 years and older, according to a December data brief published by the National Center ...
(HealthDay News) — Many general practitioners prescribe antibiotics for suspected community-acquired pneumonia (CAP) even when chest radiograph (CR) results are negative, according to a study ...
The single-arm, open-label APPULSE-PNH trial included 52 PNH patients who were on a stable regimen with either eculizumab or ravulizumab.
According to the Company, the premixed bags were developed to reduce preparation time and the risk of preparation errors.